Effect of Atractylodes macrocephala Koidzumi in a mouse model of Zymozan-induced irritable bowel syndrome

Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder that is associated with abdominal pain, discomfort and altered bowel movements. The cause of IBS, characterized by dysfunction without anatomical abnormalities in the colon, is not well known. Atractylodes macrocephala Koidzumi (AMK) is a traditional herbal medicine widely used in East Asia for the treatment of digestive system diseases. We investigated the effect and related mechanism of AMK in the treatment of IBS. First, we investigated the efficacy of AMK in the zymosan-induced IBS animal model. The IBS model was established by intracolonic administration of zymosan. Also, to investigate the relevant mechanisms, we used electrophysiological methods to determine the modulation of transient receptor potential (TRP) and voltage-switched Na+(NaV) ion channels. As a result, AMK oral administration showed increased colon length and decreased stool score and colon weight compared to the control group. In addition, AMK controlled weight loss without significantly affecting food intake. In the AMK administration group, mucosal thickness was reduced, similar to normal mice, and pain-related behaviour was significantly reduced. These effects were similar to those of sulfasalazine, an anti-inflammatory drug, and amitriptyline, an antidepressant. AMK inhibited TRPV1, NaV1.5 and NaV1.7 ion channels associated with IBS-mediated visceral hypersensitivity. These results suggest that AMK could be a potential therapeutic agent for IBS through its modulation of ion channels involved in pain and inflammation.

 

MissingLinkText

Conflict of Interest

The authors declare no conflict of interest.

Publikationsverlauf

Artikel online veröffentlicht:
16. November 2023